Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification and Mechanistic Analysis of a Novel Tick-Derived Inhibitor of Thrombin

W. Jablonka, M. Kotsyfakis, DM. Mizurini, RQ. Monteiro, J. Lukszo, SK. Drake, JM. Ribeiro, JF. Andersen,

. 2015 ; 10 (8) : e0133991. [pub] 20150805

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't

A group of peptides from the salivary gland of the tick Hyalomma marginatum rufipes, a vector of Crimean Congo hemorrhagic fever show weak similarity to the madanins, a group of thrombin-inhibitory peptides from a second tick species, Haemaphysalis longicornis. We have evaluated the anti-serine protease activity of one of these H. marginatum peptides that has been given the name hyalomin-1. Hyalomin-1 was found to be a selective inhibitor of thrombin, blocking coagulation of plasma and inhibiting S2238 hydrolysis in a competitive manner with an inhibition constant (Ki) of 12 nM at an ionic strength of 150 mM. It also blocks the thrombin-mediated activation of coagulation factor XI, thrombin-mediated platelet aggregation, and the activation of coagulation factor V by thrombin. Hyalomin-1 is cleaved at a canonical thrombin cleavage site but the cleaved products do not inhibit coagulation. However, the C-terminal cleavage product showed non-competitive inhibition of S2238 hydrolysis. A peptide combining the N-terminal parts of the molecule with the cleavage region did not interact strongly with thrombin, but a 24-residue fragment containing the cleavage region and the C-terminal fragment inhibited the enzyme in a competitive manner and also inhibited coagulation of plasma. These results suggest that the peptide acts by binding to the active site as well as exosite I or the autolysis loop of thrombin. Injection of 2.5 mg/kg of hyalomin-1 increased arterial occlusion time in a mouse model of thrombosis, suggesting this peptide could be a candidate for clinical use as an antithrombotic.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020443
003      
CZ-PrNML
005      
20160722120044.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0133991 $2 doi
024    7_
$a 10.1371/journal.pone.0133991 $2 doi
035    __
$a (PubMed)26244557
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jablonka, Willy $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland, United States of America.
245    10
$a Identification and Mechanistic Analysis of a Novel Tick-Derived Inhibitor of Thrombin / $c W. Jablonka, M. Kotsyfakis, DM. Mizurini, RQ. Monteiro, J. Lukszo, SK. Drake, JM. Ribeiro, JF. Andersen,
520    9_
$a A group of peptides from the salivary gland of the tick Hyalomma marginatum rufipes, a vector of Crimean Congo hemorrhagic fever show weak similarity to the madanins, a group of thrombin-inhibitory peptides from a second tick species, Haemaphysalis longicornis. We have evaluated the anti-serine protease activity of one of these H. marginatum peptides that has been given the name hyalomin-1. Hyalomin-1 was found to be a selective inhibitor of thrombin, blocking coagulation of plasma and inhibiting S2238 hydrolysis in a competitive manner with an inhibition constant (Ki) of 12 nM at an ionic strength of 150 mM. It also blocks the thrombin-mediated activation of coagulation factor XI, thrombin-mediated platelet aggregation, and the activation of coagulation factor V by thrombin. Hyalomin-1 is cleaved at a canonical thrombin cleavage site but the cleaved products do not inhibit coagulation. However, the C-terminal cleavage product showed non-competitive inhibition of S2238 hydrolysis. A peptide combining the N-terminal parts of the molecule with the cleavage region did not interact strongly with thrombin, but a 24-residue fragment containing the cleavage region and the C-terminal fragment inhibited the enzyme in a competitive manner and also inhibited coagulation of plasma. These results suggest that the peptide acts by binding to the active site as well as exosite I or the autolysis loop of thrombin. Injection of 2.5 mg/kg of hyalomin-1 increased arterial occlusion time in a mouse model of thrombosis, suggesting this peptide could be a candidate for clinical use as an antithrombotic.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a antikoagulancia $x chemie $x izolace a purifikace $x farmakologie $7 D000925
650    _2
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a vyšetření krevní srážlivosti $7 D001780
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a peptidy $x chemie $x izolace a purifikace $x farmakologie $7 D010455
650    _2
$a agregace trombocytů $x účinky léků $7 D010974
650    _2
$a sekvenční seřazení $7 D016415
650    _2
$a trombin $x antagonisté a inhibitory $x metabolismus $7 D013917
650    _2
$a trombóza $x farmakoterapie $7 D013927
650    _2
$a klíšťata $x chemie $7 D013987
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kotsyfakis, Michalis $u Institute of Parasitology, Academy of Sciences of the Czech Republic, České Budejovice, Czech Republic.
700    1_
$a Mizurini, Daniella M $u Instituto de Bioquimica Médica Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Monteiro, Robson Q $u Instituto de Bioquimica Médica Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Lukszo, Jan $u Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
700    1_
$a Drake, Steven K $u Critical Care Medicine Department, Clinical Center; National Institutes of Health, Bethesda, Maryland, United States of America.
700    1_
$a Ribeiro, José M C $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland, United States of America.
700    1_
$a Andersen, John F $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland, United States of America. $7 gn_A_00006077
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 8 (2015), s. e0133991
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26244557 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160722120258 $b ABA008
999    __
$a ok $b bmc $g 1155113 $s 944971
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 8 $d e0133991 $e 20150805 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...